Table 4.
Gene | Effect of Cyp1b1-ko |
Gene Function | Impact of gene on Type 2 Diabetes |
Ref |
---|---|---|---|---|
Scd1 | − | FA desaturation | KO increases GT | 16 |
Pdk4 | − | Pyruvate to Acetyl CoA | KO increases GT | 61 |
Me1 | − | Malate/NADP to Pyruvate | KO increases GT | 59 |
Map4k4 | − | TNF-activated kinase inhibits insulin | KO increases GT | 86 |
Pparγ | − | Stimulates TG synthesis | Liver KO lowers SH | 87 |
Spp1 | − | Sustains PPARγ/lipid droplets | KO lowers SH, glucose | 88 |
Gas6 | − | Released from Kupffer cells/ increase FA oxidation | KO lowers SH, inflamation | 89 |
Rgs16 | − | G protein activator | KO increases FA oxidation | 90 |
Vldlr | − | Very low density lipoprotein receptor | KO lowers SH | 91 |
Socs2 | + | Ubiquitin ligase, negative regulator of JAK/STAT | KO decreases insulin sensitivity | 92 |
G0s2 | − | PNPLA2 inhibitor | Tg stimulates SH | 51 |
Cidec | − | Binds lipid droplets, mediates PPARγ effects | Tg stimulates SH | 93 |
Lpin2 | − | Lipid phosphatase/PPAR co-activator | SiRNA suppresses SH | 50 |
Cyp7b1 | + | Bile acid synthesis | Tg stimulation lowers glucose | 94 |
Slco1a1 | + | Bile acid transport | Tg stimulation lowers glucose | 94 |
Cyp1b1-effects directly link to decreased T2D/SH | ||||
Hamp2 | − | Hepcidin2/ Fe stimulant | Serum hepcidin linked to T2D | 95 |
Hhex | + | Liver homeobox regulator | Mutant human marker for T2D | 96 |
Type 2 diabetes = T2D
Glucose tolerance = GT
Steatotic hepatitis = SH
Transgene = Tg